1. Scrip
  2. >>Business
  3. >>Strategy

Relay To Take On AstraZeneca With RLY-2608 In PI3Kα-Mutated Breast Cancer

 
• By Alaric DeArment

The firm is planning a head-to-head trial against AstraZeneca’s Truqap after RLY-2608 showed better safety and efficacy in a Phase I trial, including a four-month PFS benefit.

• Source: Shutterstock

AstraZeneca PLC’s PI3Kα inhibitor Truqap (capivasertib) won US Food and Drug Administration approval late last year and has quickly become the standard of care in certain patients with breast cancer, but could soon face a challenger in the form of Relay Therapeutics, Inc.’s RLY-2608, which has shown strong results in a Phase I clinical trial.

Cambridge, MA-based Relay announced interim results on 9 September from the study of RLY-2608 – an allosteric, pan-mutant and isoform-selective...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial